Cureus. 2020 Jun 20;12(6):e8717. doi: 10.7759/cureus.8717.
ABSTRACT
Asthma patients have commonly been prescribed inhaled corticosteroids (ICSs) as the first line of control therapy. ICSs are associated with an increased risk of pneumonia in chronic obstructive airway disease (COPD) patients. However, the evidence remains controversial in asthma patients. Several observational studies reported an increased risk of pneumonia; however, COPD patients were not excluded clearly in these studies. In observational studies that excluded COPD patients and in randomized controlled trials, ICS use was not found to be associated with the risk of pneumonia. Hence, COPD patients should be excluded in future studies, and the currently available evidence demonstrates that ICS use is not associated with an increased risk of pneumonia in asthma patients.
PMID:32699712 | PMC:PMC7372200 | DOI:10.7759/cureus.8717